Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773223 | 1.00 | TSHR (0.35) | TSHRTP53EGLN1EGLN3POLB | |
| SCHEMBL6508724 | 0.92 | POLB (0.31) | POLB | |
| SCHEMBL3452538 | 0.87 | POLB (0.32) | TSHRTP53EGLN1EGLN3POLB | |
| SCHEMBL3452535 | 0.87 | POLB (0.32) | TSHRTP53EGLN1EGLN3POLB | |
| SCHEMBL892513 | 0.83 | TSHR (0.44) | TSHRTP53EGLN1EGLN3POLB | |
| SCHEMBL1398495 | 0.83 | — | — | |
| SCHEMBL8922960 | 0.83 | TSHR (0.44) | TSHRTP53EGLN1EGLN3POLB | |
| SCHEMBL6678007 | 0.83 | — | — | |
| SCHEMBL821436 | 0.83 | — | — | |
| SCHEMBL892514 | 0.83 | TSHR (0.44) | TSHRTP53EGLN1EGLN3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828348-B1 | RADIATION-CURABLE COATING COMPOSITIONS | BASF SE (DE) | 2016-04-20 | — | — | EP | claimed |
| EP-2160429-B1 | FLEXIBLE RADIATION-CURABLE COATING MASSES | BASF SE (DE) | 2012-08-15 | — | — | EP | claimed |
| EP-1678094-A1 | RADIATION-HARDENABLE COATING AGENT CONTAINING ALIPHATIC URETHANE(METH)ACRYLATE | BASF AKTIENGESELLSCHAFT (DE) | 2006-07-12 | — | — | EP | claimed |
| EP-0902040-B1 | Radiation curable compositions from urethane groups containing aliphatic prepolymers having ethylenically unsaturated double bonds | BASF AG (DE) | 2005-08-03 | — | — | EP | claimed |
| WO-2005035460-A1 | RADIATION-HARDENABLE COATING AGENT CONTAINING ALIPHATIC URETHANE(METH)ACRYLATE | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | claimed |
| EP-1957557-B1 | RADIATION-CURABLE DISPERSIBLE POLYURETHANES AND POLYURETHANE DISPERSIONS | BASF SE (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| EP-2758185-B1 | METHOD FOR COATING WHEEL RIMS OF LIGHT METALS | BASF SE (DE) | 2018-11-14 | — | — | EP | disclosed |
| EP-2462177-B2 | RADIATION-CURABLE, WATER-DISPERSIBLE POLYURETHANES AND POLYURETHANE DISPERSIONS | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-1856173-B1 | RADIATION-CURABLE AQUEOUS POLYURETHANE DISPERSIONS | BASF SE (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2414316-B1 | METHOD FOR PRODUCING SOLUTIONS OF RADIATION-SENSITIVE, RADICALLY POLYMERIZABLE ORGANIC COMPOUNDS | BASF SE (DE) | 2016-11-30 | — | — | EP | disclosed |
| WO-2005035460-A1 | RADIATION-HARDENABLE COATING AGENT CONTAINING ALIPHATIC URETHANE(METH)ACRYLATE | BASF AKTIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | WO | disclosed |
| EP-1144476-B1 | COATING AGENTS WHICH CAN BE HARDENED BY THE ADDITION OF ISOCYANATE GROUPS AS WELL AS BY THE RADIATION-INDUCED ADDITION OF ACTIVATED C-C DOUBLE COVALENT BONDS | BASF AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| EP-1141068-B1 | ISOCYANATE-BASED CURABLE PREPARATIONS | BASF AG (DE) | 2002-07-31 | — | — | EP | disclosed |
| EP-1144476-A1 | COATING AGENTS WHICH CAN BE HARDENED BY THE ADDITION OF ISOCYANATE GROUPS AS WELL AS BY THE RADIATION-INDUCED ADDITION OF ACTIVATED C-C DOUBLE COVALENT BONDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000039183-A1 | COATING AGENTS WHICH CAN BE HARDENED BY THE ADDITION OF ISOCYANATE GROUPS AS WELL AS BY THE RADIATION-INDUCED ADDITION OF ACTIVATED C-C DOUBLE COVALENT BONDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-06 | — | — | WO | disclosed |
| EP-0903363-A1 | Process for the preparation of radiation-curable prepolymers containing urethane groups | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-24 | — | — | EP | disclosed |
| EP-0902040-A1 | Radiation curable compositions from urethane groups containing aliphatic prepolymers having ethylenically unsaturated double bonds | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-17 | — | — | EP | disclosed |
| US-5221753-A | PREPARATION OF 1-(4-TETRAHYDROPYRANYL)- OR 1-(4-TETRAHYDROTHIOPYRANYL)PROP-1-EN-3-ONES | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | TSHR 2353/4885TP53 909/4885EGLN1 1362/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | TSHR 2353/4885TP53 909/4885EGLN1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.